<DOC>
	<DOCNO>NCT01622556</DOCNO>
	<brief_summary>This phase II study assess day 180 event free overall survival administration specify combination fludarabine , busulfan , Total Body Irradiation ( TBI ) , thymoglobulin reduce intensity condition 2 unit UCB stem cell transplant single institution set patient hematologic malignancy allogeneic transplantation indicate .</brief_summary>
	<brief_title>Conditioning Treatment With Umbilical Cord Blood Transplant Hematologic Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>Subjects 1870 year old . ECOG 02 Patients must diagnosis one following : Chronic Myeloid Leukemia Acute Myeloid Leukemia Acute Lymphoblastic Leukemia Hodgkin 's Disease NonHodgkins Lymphoma Myelodysplastic Syndromes Myeloproliferative Disorder Patients must adequate visceral organ function Patients must furnish write informed consent HIPAA authorization release personal health information . Patients must able understand requirement study , abide study restriction , agree return require assessment . Patients histocompatible siblingmatched donor age 18 65 year good health willing donate stem cell ineligible . Patients pregnant ineligible . Patients ineligible receive cumulative chemotherapy dose excess : carmustine ( BCNU ) 400 mg/m2 , and/or cumulative anthracycline exposure excess 550 mg/m2 doxorubicin ( AdriamycinÂ® ) unless gatedpool radionuclide cardiac scan show great than/equal 45 % ejection fraction . Patients HIV HTLVI , II antibody seropositive ineligible .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Chronic Myeloid Leukemia</keyword>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>Acute Lymphoblastic Leukemia</keyword>
	<keyword>Non-Hodgkins Lymphoma</keyword>
	<keyword>Hodgkin 's Disease</keyword>
	<keyword>Myelodysplastic Syndromes</keyword>
	<keyword>Myeloproliferative Disorder</keyword>
</DOC>